Table 1.

Distribution at enrollment of demographic characteristics and possible risk factors for acid-related findings by diabetic status among 1569 men and women undergoing esophagogastroduodenoscopy (EGD).

	Diabetic Patients		Non-Diabetic
Characteristic			Patients		p-value
Gender	N	%	N	%
Male	166	64.8	716	54.6	.00
Female	90	35.2	595	45.4
Age (years)
< 50	31	12.1	331	25.3	<.0001
50 – 59	66	25.8	238	26.6
60 – 69	89	34.8	344	26.3
≥ 70	70	27.3	286	21.9
Mean Age (SD)	62.9	(11.4)	58.0	(14.4)	<.0001
Race/Ethnicity
White	194	75.8	1105	84.2	.00
Black	25	9.8	60	4.6
Asian/Pacific Islander	2	0.8	7	0.5
American Indian/Alaskan Native	9	3.5	31	2.4
Multi-racial	12	4.7	21	1.6
Hispanic (any race)	14	5.5	73	5.6
Other/Refused	0	0.0	16	1.2
Height (in)
Mean (SD)	67.8	(4.0)	67.7	(3.9)	.48
Weight (lbs)
Mean (SD)	204.4	(46.4)	181.1	(42.4)	<.0001
Body Mass Index (kg/m2) Categories
< 25	45	17.7	438	33.6	<.0001
25 to < 30	75	29.5	470	36.0
≥30	134	52.8	397	30.4
Body Mass Index Mean (SD)	31.2	(6.9)	27.7	(5.5)	<.0001
Self-reported medical history
Acid-reflux	180	70.6	914	69.8	0.79
Heartburn	54	21.3	393	30.0	.01
Previous upper GI disease*	126	51.0	576	44.8	.07
Any PPI† use	144	56.3	721	54.9	.69
H2 Blocker‡ use	20	7.8	117	8.9	.57
NSAID§ use	27	10.6	208	15.8	.03

SD = Standard deviation

^*Previous upper GI disease includes any one of the following: Gastroparesis, Peptic Ulcer disease, Gastritis, Esophagitis

^†PPI use includes any of the following: Lansoprazole, Omeprazole, Rabeprazole, Pantoprozole, Esomeprazole

^‡H2 Blocker use includes any of the following: Famotidine, Nizatidine, Ranitidine, Cimetidine

^§NSAID use includes prescription and over the counter